Literature DB >> 310858

Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten-reactive T lymphocytes.

T Hamaoka, H Fujiwara, K Teshima, H Aoki, H Yamamoto, M Kitagawa.   

Abstract

2,4.6-trinitrophenyl (TNP)-reactive T-cell activities were raised in mice by immunization with TNP-isologous mouse gamma globulin. After establishing that TNP-reactive T lymphocytes can serve as amplifier cells for induction of killer T lymphocytes in allogeneic system, we explored the possibility of this hapten-reactive T-cell system to amplify tumor-specific killer T-lymphocyte activity in the syngeneic system. We utlized relatively weak immunogenic syngeneic plasmacytoma X5563 in C3H/He mice. Analysis of the TNP-reactive T-cell activities revealed that such T lymphocytes express the biological functions of both major subtypes of regulatory T cells, namely suppressors and helpers, and that TNP-reactive suppressor and helper T lymphocytes, respectively, differ in their relative susceptibility to specific inactivation by TNP conjugates of the nonimmunogenic D-amino acid copolymer, D-glutamic acid, and D-lysine (D-GL). By taking advantage of the relative susceptibility-difference to TNP-D-GL, selective inactivation of TNP-reactive suppressor T cells was induced by appropriate treatment with TNP-D-GL, and the generation of TNP-reactive helper T-cell activity was amplified. The supplement of augmented TNP-reactive helper T-cell activity to the system at the immunization with syngeneic X5563 with TNP-haptenation, resulted in a striking augmentation of induction of tumor-specific killer T-lymphocyte activity, and a considerable number of hosts survived after the challenge with lethal dose of viable tumor cells. Thus, appropriate manipulations designed to induce potent hapten-reactive helper T-lymphocytes provided the potential for a very effective mode of immunoprophylaxis against tumor.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 310858      PMCID: PMC2184739          DOI: 10.1084/jem.149.1.185

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  Induction of transplantation immunity by dansylated tumor cells.

Authors:  Y Hashimoto; B Yamanoha
Journal:  Gan       Date:  1976-04

2.  Induction of immune responsiveness in a genetically low-responsive tumor-host combination by chemical modification of the immunogen.

Authors:  N Galili; D Naor; B Asjö; G Klein
Journal:  Eur J Immunol       Date:  1976-07       Impact factor: 5.532

3.  Quantitation of in vivo growth of plasmacytoma X5563 by immunoassay for its paraprotein with individual antigenic specificity.

Authors:  M Yutoku; H Seno; S Watanabe; Y Matsuoka; M Kitagawa
Journal:  J Natl Cancer Inst       Date:  1972-11       Impact factor: 13.506

4.  Immunologic approach to cancer.

Authors:  N A Mitchison
Journal:  Transplant Proc       Date:  1970-03       Impact factor: 1.066

5.  An immunogenic polysaccharide-protein conju- gate.

Authors:  R J Fielder; C T Bishop; S F Grappel; F Blank
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

6.  Immune maturation of T lymphocytes: sequential changes in the functional specificity and apparent affinity of hapten-reactive helper T cells during an immune response.

Authors:  U Yamashita; T Hamaoka; T Takami; M Kitagawa
Journal:  Cell Immunol       Date:  1976-03-01       Impact factor: 4.868

7.  Further studies on Th-B, a cell surface antigenic determinant present on mouse B cells, plasma cells and immature thymocytes.

Authors:  M Yutoku; A L Grossberg; R Stout; L A Herzenberg; D Pressman
Journal:  Cell Immunol       Date:  1976-04       Impact factor: 4.868

8.  Inhibitory effect of tumor-bearing state on the generation of in vivo protective immune T cells in a syngeneic murine tumor system.

Authors:  H Fujiwara; T Hamaoka; Y Nishino; M Kitagawa
Journal:  Gan       Date:  1977-10

9.  Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia.

Authors:  S K Lee; R T Oliver
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

10.  Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. II. Selective inactivation of hapten-reactive suppressor T cells by hapten-nonimmunogenic copolymers of D-amino acids, and its application to the study of suppressor T-cell effect on helper T-cell development.

Authors:  T Hamaoka; M Yoshizawa; H Yamamoto; M Kuroki; M Kitagawa
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

2.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.

Authors:  H Sano; A Kosugi; S Sano; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Augmentation of generation of human allospecific cytotoxic T lymphocyte by PPD in in vitro sensitization culture.

Authors:  R Ohno; Y Kodera; H Yamada
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.

Authors:  S Sato; H Fujiwara; A Kosugi; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Retention of immunogenicity after X-irradiation of mouse colon tumor cells expressing the transfected influenza virus hemagglutinin gene.

Authors:  T Itaya; B Hunt; P Frost
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice.

Authors:  A Vyakarnam; P J Lachmann; K Sikora
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

8.  The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.

Authors:  T Yoshioka; M Fukuzawa; Y Takai; N Wakamiya; S Ueda; S Kato; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.

Authors:  T Hamaoka; Y Takai; A Kosugi; Y Mizushima; J Shima; T Kusama; H Fujiwara
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.

Authors:  A Kosugi; J Shima; H Sano; M Ogata; T Kusama; H Fujiwara; T Hamaoka
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.